PAI
JSPR icon

Palo Alto Investors’s Jasper Therapeutics JSPR Stock Holding History

Palo Alto Investors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,651
Closed -$655K – 45
2024
Q4 		$655K Buy
+30,651
New +$638K 0.1% 37

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Palo Alto Investors's JSPR Position: Q1 2025 in Review

Palo Alto Investors sold out of Jasper Therapeutics (JSPR) in Q1 2025, closing a stake of 30,651 shares — an estimated $655K sold.

Palo Alto Investors first reported a position in JSPR in Q4 2024 and held it in 1 quarter. The position peaked at $655K in Q4 2024. 68 funds tracked by Wall St. Rank hold JSPR as of Q1 2025.

  • Palo Alto Investors reported no remaining Jasper Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Palo Alto Investors sold 30,651 Jasper Therapeutics shares in Q1 2025, an estimated $655K.
  • Palo Alto Investors first reported a position in Jasper Therapeutics in Q4 2024 and held it in 1 quarter.
  • Palo Alto Investors's Jasper Therapeutics position peaked at $655K in Q4 2024.
  • 68 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2025.

Based on Palo Alto Investors's 13F filing for Q1 2025, filed 15 May 2025.